Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) CEO Doug Ward takes Proactive’s Stephen Gunnion through the company’s achievements in 2024 and plans for the year ahead. Ward highlighted several key milestones, including the signing of a strategic partnership with Hologic and progress with its flagship products, ViraDx and FebriDx. He emphasised that FebriDx is transforming treatment by differentiating between bacterial and viral infections, helping to combat antibiotic resistance.
Ward also discussed Lumos’s collaboration with the Biomedical Advanced Research and Development Authority (BARDA), which funded a clinical trial to expand FebriDx’s accessibility. He noted, “This is a huge win for Lumos, enabling us to go from 18,000 locations to 220,000 locations in the US with CLIA waivers.”
Furthermore, the company successfully secured A$10.00 million in funding, attracting key investors like Tenmile and Ryder Capital. Ward expressed optimism for 2025, focusing on revenue growth, the BARDA-funded trial, and enhancing their partnerships.